New scan aims to better detect liver tumors
NCT ID NCT07353333
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study will test a special imaging agent that targets a protein found on liver cancer cells. Six people with suspected or confirmed liver cancer will receive a low-dose radioactive tracer and then have a SPECT-CT scan. The goal is to see how the tracer moves through the body and whether it can help doctors see tumors more clearly. This is a first step to see if the method is safe and could be used for future treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430030, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new scanner match the gold standard in nuclear imaging?
- A made-to-order DNA vaccine takes aim at liver cancer's return
- Simple blood test aims to catch liver cancer before It's too late
- Engineered virus takes on liver cancer when standard treatment fails
- Ultrasound vs. MRI: which spots hidden liver cancer better?
- Epigenetic drug may re-sensitize liver tumors to immunotherapy